Groowe Groowe / Newsroom / OCS
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

OCS News

Oculis Holding AG Ordinary shares

Oculis Announces FDA IND Clearance Enabling Acceleration of Privosegtor Development Program in Acute Multiple Sclerosis Relapses

globenewswire.com
OCS

Oculis Holding AG: Samningur um viðskiptavakt við Fossa fjárfestingarbanka hf.

globenewswire.com
OCS

Oculis to Host In-Person and Virtual R&D Day: Advancing a Differentiated Late-Stage Development Pipeline

globenewswire.com
OCS

Oculis to Host In-Person and Virtual R&D Day: Advancing a Differentiated Late-Stage Development Pipeline

globenewswire.com
OCS

Oculis Reports Q3 2026 Financial Results and Builds Momentum Toward Multiple Upcoming Pipeline Catalysts

globenewswire.com
OCS

Oculis Reports Q3 2026 Financial Results and Builds Momentum Toward Multiple Upcoming Pipeline Catalysts

globenewswire.com
OCS

Oculis Appoints Experienced Life Sciences Leader Björn Tackenberg, M.D., Ph.D., as Chief Scientific Officer to Advance Neurology Innovation

globenewswire.com
OCS

Oculis Appoints Experienced Life Sciences Leader Björn Tackenberg, M.D., Ph.D., as Chief Scientific Officer to Advance Neurology Innovation

globenewswire.com
OCS

Oculis to Feature Privosegtor’s Neuroprotective Potential and Ongoing PIONEER Program at APOIS Congress and CNS Summit

globenewswire.com
OCS

Oculis to Feature Privosegtor’s Neuroprotective Potential and Ongoing PIONEER Program at APOIS Congress and CNS Summit

globenewswire.com
OCS